HomeCompareCMPVF vs ABBV

CMPVF vs ABBV: Dividend Comparison 2026

CMPVF yields 0.17% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $66.0K in total portfolio value
10 years
CMPVF
CMPVF
● Live price
0.17%
Share price
$33.66
Annual div
$0.06
5Y div CAGR
76.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36.4K
Annual income
$7,577.64
Full CMPVF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CMPVF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMPVFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMPVF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMPVF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMPVF
Annual income on $10K today (after 15% tax)
$14.83/yr
After 10yr DRIP, annual income (after tax)
$6,440.99/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $14,615.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMPVF + ABBV for your $10,000?

CMPVF: 50%ABBV: 50%
100% ABBV50/50100% CMPVF
Portfolio after 10yr
$69.4K
Annual income
$16,174.70/yr
Blended yield
23.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CMPVF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMPVF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMPVFABBV
Forward yield0.17%3.06%
Annual dividend / share$0.06$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR76.7%40.6%
Portfolio after 10y$36.4K$102.3K
Annual income after 10y$7,577.64$24,771.77
Total dividends collected$15.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CMPVF vs ABBV ($10,000, DRIP)

YearCMPVF PortfolioCMPVF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,731$30.83$11,550$430.00$819.00ABBV
2$11,537$54.63$13,472$627.96$1.9KABBV
3$12,441$96.98$15,906$926.08$3.5KABBV
4$13,485$172.71$19,071$1,382.55$5.6KABBV
5$14,738$309.14$23,302$2,095.81$8.6KABBV
6$16,327$557.96$29,150$3,237.93$12.8KABBV
7$18,491$1,020.80$37,536$5,121.41$19.0KABBV
8$21,695$1,909.16$50,079$8,338.38$28.4KABBV
9$26,912$3,698.99$69,753$14,065.80$42.8KABBV
10$36,374$7,577.64$102,337$24,771.77$66.0KABBV

CMPVF vs ABBV: Complete Analysis 2026

CMPVFStock

CompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment provides practice management software and electronic medical records for registered physicians, medical care centers, and physicians networks, as well as offers supplementary Internet and intranet solutions. The PCS segment provides administrative and billing-related software applications for pharmacies. Its software solution provides information and decision support to manage various aspects of supply chain for medication. The HIS segment provides clinical and administrative solutions for the inpatient sector. This segment serves acute care hospitals, rehabilitation centers, social services, multi-location hospital networks and regional care organizations, and medical laboratories. The CHS segment provides IT security services, data-based product offers, software interface for sharing of information, clinical decision-making support, and medication and treatment databases for healthcare service providers, as well as digital healthcare stock, consumer portals, and mobile apps. This segment also offers security solutions for healthcare providers. It serves pharmaceutical companies, health insurance companies, and other healthcare IT companies and consumers. The company was formerly known as CompuGroup Medical SE and changed its name to CompuGroup Medical SE & Co. KGaA in June 2020. CompuGroup Medical SE & Co. KGaA was founded in 1987 and is headquartered in Koblenz, Germany.

Full CMPVF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CMPVF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMPVF vs SCHDCMPVF vs JEPICMPVF vs OCMPVF vs KOCMPVF vs MAINCMPVF vs JNJCMPVF vs MRKCMPVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.